Nektar Therapeutics (NASDAQ:NKTR) saw some unusual options trading on Wednesday. Stock investors acquired 1,897 put options on the stock. This represents an increase of 954% compared to the typical volume of 180 put options.

In related news, CEO Howard W. Robin sold 83,334 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the completion of the sale, the chief executive officer now directly owns 235,838 shares in the company, valued at approximately $5,558,701.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the sale, the chief executive officer now owns 272,768 shares of the company’s stock, valued at $15,190,449.92. The disclosure for this sale can be found here. Insiders have sold a total of 614,017 shares of company stock valued at $20,587,527 over the last 90 days. 5.44% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. Janus Henderson Group PLC purchased a new stake in Nektar Therapeutics in the 2nd quarter worth approximately $34,661,000. PointState Capital LP lifted its holdings in Nektar Therapeutics by 281.7% in the 2nd quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after buying an additional 1,277,500 shares during the period. Rubric Capital Management LP purchased a new position in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $23,924,000. State Street Corp lifted its stake in shares of Nektar Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after purchasing an additional 447,023 shares during the period. Finally, Numeric Investors LLC lifted its stake in shares of Nektar Therapeutics by 2,111.5% in the 2nd quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock valued at $8,616,000 after purchasing an additional 420,800 shares during the period. Institutional investors and hedge funds own 96.01% of the company’s stock.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $72.00 on Friday. Nektar Therapeutics has a fifty-two week low of $11.41 and a fifty-two week high of $73.95. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. The firm has a market capitalization of $11,340.00, a P/E ratio of -101.41 and a beta of 1.81.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a return on equity of 557.76% and a net margin of 39.80%. The business had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter last year, the business posted ($0.32) EPS. The business’s revenue was up 321.2% on a year-over-year basis. sell-side analysts forecast that Nektar Therapeutics will post -0.75 earnings per share for the current year.

Several equities research analysts recently weighed in on NKTR shares. Roth Capital set a $45.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Canaccord Genuity Group increased their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, November 15th. Mizuho increased their target price on Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 14th. Cowen started coverage on Nektar Therapeutics in a report on Tuesday, November 7th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 target price on shares of Nektar Therapeutics in a report on Monday, November 13th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and an average price target of $38.08.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/13/stock-traders-purchase-large-volume-of-nektar-therapeutics-put-options-nktr.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.